Moby summary of MaxCyte, Inc.'s Q3 2026 earnings call
Why Is MaxCyte, Inc. (MXCT) Stock Up Today?
Updated Nov 22, 2026 6:42 AM ET ยท Prev Close $1.28
Session Regime & Catalyst Assessment
68% Signal ConvictionMaxCyte, Inc. Advancing 7.03% on 0.77x Relative Volume
MaxCyte, Inc. (MXCT) is advancing 7.03% (+$0.09) to $1.37 on 0.77x average session volume. Relative to benchmarks, MXCT is outperforming the S&P 500 by +10.67%. 14-day RSI stands at 55.3, keeping momentum in a bullish regime.
Moby summary of MaxCyte, Inc.'s Q3 2026 earnings call
Price ($1.37) holds above both 20-day ($1.36) and 50-day ($1.25) moving averages.
Market & Sector Relative Strength
MXCT outperforming the S&P 500 by +10.67%Options Flow & Execution Desk
Recent MXCT Catalyst Headlines
Verified WireManagement sees its Akron Bio deal accelerating the path to profitability ahead.
MaxCyte Inc MXCT posted strong Q3 2026 revenue growth and unveiled a transformative 151.8 million Accron acquisition expected to accelerate profitability and diversify its customer base.
MaxCyte Nasdaq Mxct reported 49 third-quarter revenue growth and raised its 2026 revenue outlook, while announcing an agreement to acquire cell therapy materials supplier Akron Bio for 151.8 million. The transaction, whi
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $1.36 (20-day SMA support) for directional breakout confirmation.
Technical Regime (MXCT)
BULLISH MA TRENDRetail & Crowd Sentiment
QuietMaxCyte announced management will participate in three upcoming investor conferences.
About MaxCyte, Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The โฆ
Get Instant MXCT Catalyst Alerts
Receive an email alert when MXCT triggers an unusual volume breakout, options sweep, or rating shift.
MXCT Session & Catalyst FAQ
Why is MXCT stock up today?
MaxCyte, Inc. (MXCT) is advancing 7.03% (+$0.09) to $1.37 on 0.77x average session volume. Relative to benchmarks, MXCT is outperforming the S&P 500 by +10.67%. 14-day RSI stands at 55.3, keeping momentum in a bullish regime.
Is MXCT stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.77x relative volume (low participation). Our multi-factor model currently rates MXCT as HOLD. Review full valuation, quality, and timing signals on the MXCT Buy or Sell Decision Brief โ
What is MXCT's intrinsic value and expected trading range?
At $1.37, MXCT's modeled 1-to-3 session range is $1.29 โ $1.45, with a key inflection level at $1.36 (20-day SMA support). Compare current price against multi-year cash flow projections in the MXCT Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for MXCT?
RSI at 55.3 reflects constructive bullish momentum. MXCT trades at $1.37 relative to its 20-day SMA ($1.36) and 50-day SMA ($1.25), reflecting a bullish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.